Do Analysts Think Akebia Therapeutics Inc. (AKBA) Is Still Worth Buying In 2024?

Akebia Therapeutics Inc. (NASDAQ:AKBA) does about 5.15M shares in volume on a normal day but saw 2311610 shares change hands in Friday’s trading. The company now has a market cap of 253.60M USD. Its current market price is $1.21, marking a decrease of -9.02% compared to the previous close of $1.33. The 52 week high reached by this stock is $2.48 whilst the lowest price level in 52 weeks is $0.78.

Akebia Therapeutics Inc. (AKBA) has a 20-day trading average at $1.3510 and the current price is -51.21% off the 52-week high compared with 55.11% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.5436 and its 200-day simple moving average is $1.3275. If we look at the stock’s price movements over the week, volatility stands at 13.42%, which decreases to 7.54% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 36.74 to suggest the stock is neutral.

The consensus objective for the share price is $5.00, suggesting that the stock has a potential upside of 75.8% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 29, 2023 when BTIG Research resumed the stock to “Buy” and issued a price target of $4. H.C. Wainwright upgraded the stock to “Buy” from Neutral on August 28, 2023 at a price target of $3.75. Piper Sandler upgraded its price target at $2-$4.

Akebia Therapeutics Inc. (AKBA) stock is down -11.68% over the week and -20.92% over the past month. Its price is -2.42% year-to-date and 17.48% over the past year.

To reach the target analysts have set, the stock logically needs to grow 75.8 percent from here.

The company has a return on investment of -67.22% and return on equity of -554.87%. The beta has a value of 0.83. Price to sales ratio is 1.35.